Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

parsaclisib (INCB50465)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Incyte, Innovent Biologics

Drug class:

PI3Kδ inhibitor

Related drugs:

No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	INCB50465 Sensitive: B - Late Trials INCB50465 Sensitive : B	INCB50465 Sensitive: B - Late Trials INCB50465 Sensitive : B
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	INCB50465 Sensitive: B - Late Trials INCB50465 Sensitive : B	INCB50465 Sensitive: B - Late Trials INCB50465 Sensitive : B
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	INCB50465 Sensitive: B - Late Trials INCB50465 Sensitive : B	INCB50465 Sensitive: B - Late Trials INCB50465 Sensitive : B
CCND1 overexpression	Mantle Cell Lymphoma	CCND1 overexpression	Mantle Cell Lymphoma	INCB50465 Sensitive: C2 – Inclusion Criteria INCB50465 Sensitive : C2	INCB50465 Sensitive: C2 – Inclusion Criteria INCB50465 Sensitive : C2
Chr t(11;14)	Mantle Cell Lymphoma	Chr t(11;14)	Mantle Cell Lymphoma	INCB50465 Sensitive: C3 – Early Trials INCB50465 Sensitive : C3	INCB50465 Sensitive: C3 – Early Trials INCB50465 Sensitive : C3
CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	obinutuzumab + INCB50465 Sensitive: C3 – Early Trials obinutuzumab + INCB50465 Sensitive : C3	obinutuzumab + INCB50465 Sensitive: C3 – Early Trials obinutuzumab + INCB50465 Sensitive : C3